MARINA KONOPLEVA to Aminopyridines
This is a "connection" page, showing publications MARINA KONOPLEVA has written about Aminopyridines.
Connection Strength
0.530
-
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10.
Score: 0.176
-
Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019 06; 32(2):145-153.
Score: 0.146
-
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
Score: 0.123
-
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.
Score: 0.042
-
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021 05 03; 218(5).
Score: 0.042